UA99555C2 - Melanocortin receptor agonists - Google Patents

Melanocortin receptor agonists

Info

Publication number
UA99555C2
UA99555C2 UAA201105960A UAA201105960A UA99555C2 UA 99555 C2 UA99555 C2 UA 99555C2 UA A201105960 A UAA201105960 A UA A201105960A UA A201105960 A UAA201105960 A UA A201105960A UA 99555 C2 UA99555 C2 UA 99555C2
Authority
UA
Ukraine
Prior art keywords
melanocortin receptor
receptor agonists
agonistic
isomer
melanocortin
Prior art date
Application number
UAA201105960A
Other languages
English (en)
Ukrainian (uk)
Inventor
Коо Ли
Санг Дае Ли
Санг Пил Моон
Ин Ае Ахн
Сунг Пил Чой
Хьюн Хо Ли
Донг Сап Шим
Соо Йонг Чанг
Хьюн Мин Ли
Original Assignee
Элджи Лайф Саенсез Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Элджи Лайф Саенсез Лтд. filed Critical Элджи Лайф Саенсез Лтд.
Publication of UA99555C2 publication Critical patent/UA99555C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Данное изобретение касается соединения с высокой агонистической активностью к рецептору меланокортина или его фармацевтически приемлемой соли или изомера, а также агонистической к рецептору меланокортина композиции, которая содержит указанное соединение или его фармацевтически приемлемую соль или изомер как активный ингредиент.
UAA201105960A 2008-11-12 2009-10-11 Melanocortin receptor agonists UA99555C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20080112403 2008-11-12

Publications (1)

Publication Number Publication Date
UA99555C2 true UA99555C2 (en) 2012-08-27

Family

ID=42165801

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201105960A UA99555C2 (en) 2008-11-12 2009-10-11 Melanocortin receptor agonists

Country Status (26)

Country Link
US (4) US8288386B2 (ru)
EP (1) EP2350060B1 (ru)
JP (1) JP5399506B2 (ru)
KR (1) KR101141976B1 (ru)
CN (1) CN102282141B (ru)
AR (1) AR074109A1 (ru)
AU (1) AU2009314827B2 (ru)
BR (1) BRPI0921063B8 (ru)
CA (1) CA2742248C (ru)
CL (1) CL2011001073A1 (ru)
CO (1) CO6362006A2 (ru)
CR (1) CR20110250A (ru)
EA (1) EA019146B1 (ru)
EC (1) ECSP11011026A (ru)
GE (1) GEP20135850B (ru)
IL (1) IL212468A0 (ru)
MA (1) MA32774B1 (ru)
MX (1) MX2011004583A (ru)
NZ (1) NZ592512A (ru)
PE (1) PE20110684A1 (ru)
TN (1) TN2011000222A1 (ru)
TW (1) TWI389903B (ru)
UA (1) UA99555C2 (ru)
UY (1) UY32238A (ru)
WO (1) WO2010056022A2 (ru)
ZA (1) ZA201103154B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
KR20150013137A (ko) 2012-04-25 2015-02-04 에프. 호프만-라 로슈 아게 (3,4-다이클로로-페닐)-((s)-3-프로필-피롤리딘-3-일)-메탄온 하이드로클로라이드 및 제조 방법
CN103420981A (zh) * 2012-05-21 2013-12-04 中国医学科学院药物研究所 含有取代吡咯烷基的硫代吗啉类化合物
SG10202101510XA (en) 2015-09-30 2021-03-30 Rhythm Pharmaceuticals Inc Method of treating melanocortin-4 receptor pathway-associated disorders
AU2019249255A1 (en) 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
ES2970510T3 (es) 2019-11-07 2024-05-29 Lg Chemical Ltd Agonistas del receptor de melanocortina-4
AU2021371829B2 (en) 2020-10-29 2024-01-18 Lg Chem, Ltd. Crystalline form ii of melanocortin receptor agonist compound and preparation method therefor
EP4219472A4 (en) * 2020-10-29 2024-03-13 Lg Chem, Ltd. CRYSTALLINE FORM I OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
MX2023004731A (es) * 2020-10-29 2023-05-10 Lg Chemical Ltd Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma.
KR102672626B1 (ko) * 2020-10-29 2024-06-07 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅲ 및 이의 제조방법
WO2022092908A1 (ko) * 2020-10-29 2022-05-05 주식회사 엘지화학 무정형의 멜라노코르틴-4 수용체 작용제
KR20220090455A (ko) 2020-12-22 2022-06-29 주식회사 엘지화학 무정형의 멜라노코르틴 수용체 작용제 및 이의 제조방법
TWI814185B (zh) * 2020-12-22 2023-09-01 南韓商Ｌｇ化學股份有限公司 黑皮質素受體促效劑化合物之晶型ii及其製備方法
US20240043407A1 (en) * 2020-12-22 2024-02-08 Lg Chem, Ltd. Crystalline form i of melanocortin receptor agonist compound and method for preparing same
IL303822A (en) * 2020-12-22 2023-08-01 Lg Chemical Ltd Use as a selective melanocortin-4 receptor agonist
EP4249485A4 (en) 2020-12-22 2024-05-15 Lg Chem, Ltd. CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR
WO2022158868A1 (ko) * 2021-01-21 2022-07-28 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 용도
EP4299572A4 (en) * 2021-02-26 2024-07-31 Lg Chemical Ltd MELANOCORTIN-4 RECEPTOR AGONIST
CN117255786A (zh) * 2021-05-06 2023-12-19 株式会社Lg 化学 黑皮质素受体激动剂化合物的晶型vii及其制备方法
EP4317149A4 (en) * 2021-05-06 2024-08-21 Lg Chemical Ltd CRYSTALLINE FORM V OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PREPARATION THEREOF
MX2023013128A (es) 2021-05-07 2023-11-28 Lg Chemical Ltd Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos.
JP2024517271A (ja) * 2021-05-07 2024-04-19 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物の有機酸塩の結晶形ｉｖおよびその製造方法
EP4321512A4 (en) * 2021-05-07 2024-08-21 Lg Chemical Ltd CO-CRYSTAL OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND VANILLIN AND METHOD FOR THE PRODUCTION THEREOF

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534503B1 (en) * 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
JP2003505435A (ja) 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体ゴニストとしての置換ピペリジン
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
WO2001070337A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU4929601A (en) 2000-03-23 2001-10-03 Merck & Co Inc Substituted piperidines as melanocortin receptor agonists
GB0019359D0 (en) * 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
AU2001288285B2 (en) 2000-08-23 2005-09-29 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
US7291619B2 (en) 2001-01-23 2007-11-06 Eli Lilly And Company Melanocortin receptor agonists
WO2002059107A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
WO2002059095A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Melanocortin receptor agonists
KR20030076716A (ko) 2001-02-28 2003-09-26 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체
US7015235B2 (en) 2001-02-28 2006-03-21 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
ATE430565T1 (de) 2001-02-28 2009-05-15 Merck & Co Inc Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
AR043434A1 (es) 2003-03-03 2005-07-27 Merck & Co Inc Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
ATE474577T1 (de) 2003-03-26 2010-08-15 Merck Sharp & Dohme Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US7989634B2 (en) * 2003-11-12 2011-08-02 Lg Life Sciences Ltd. Melanocortin receptor agonists
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US20080051430A1 (en) 2004-07-16 2008-02-28 Barakat Khaled J Acylated Piperidine Derivatives as Melanocortin 4-Receptor Agonists
DE602005018779D1 (de) 2004-07-19 2010-02-25 Merck & Co Inc Acylierte piperidinderivative als melanocortin-4-rezeptoragonisten
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20080234280A1 (en) 2005-08-01 2008-09-25 Mcmurray Gordon Use of Mc4 Receptor Agonist Compounds
JP2009503050A (ja) 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20100160306A1 (en) 2005-09-30 2010-06-24 Bakshi Raman K Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
AU2006304305B2 (en) 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2007131570A (ja) 2005-11-09 2007-05-31 Mitsubishi Pharma Corp 新規なアミノピロリジン誘導体
WO2007096186A1 (en) 2006-02-23 2007-08-30 Santhera Pharmaceuticals (Schweiz) Ag Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators
WO2007096763A2 (en) 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
AU2007255366B2 (en) 2006-06-09 2013-07-18 Synact Pharma Aps Phenyl pyrrole aminoguanidine derivatives
TWI332501B (en) 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
US20090253744A1 (en) 2006-09-27 2009-10-08 Bakshi Raman K Acylated piperidine derivatives as melanocortin-4 receptor modulators
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists

Also Published As

Publication number Publication date
AU2009314827B2 (en) 2012-04-05
NZ592512A (en) 2012-12-21
WO2010056022A3 (en) 2010-09-10
US8236955B2 (en) 2012-08-07
CR20110250A (es) 2011-08-26
BRPI0921063B8 (pt) 2021-05-25
PE20110684A1 (es) 2011-09-28
BRPI0921063B1 (pt) 2021-03-16
US20110237795A1 (en) 2011-09-29
GEP20135850B (en) 2013-06-10
KR20100053458A (ko) 2010-05-20
CA2742248A1 (en) 2010-05-20
TW201022246A (en) 2010-06-16
EA201170676A1 (ru) 2011-12-30
EP2350060A2 (en) 2011-08-03
JP5399506B2 (ja) 2014-01-29
US8039622B2 (en) 2011-10-18
TWI389903B (zh) 2013-03-21
KR101141976B1 (ko) 2012-05-07
CN102282141A (zh) 2011-12-14
TN2011000222A1 (en) 2012-12-17
US8288386B2 (en) 2012-10-16
EA019146B1 (ru) 2014-01-30
IL212468A0 (en) 2011-06-30
UY32238A (es) 2010-01-05
AU2009314827A1 (en) 2010-05-20
WO2010056022A2 (en) 2010-05-20
US20100120783A1 (en) 2010-05-13
MA32774B1 (fr) 2011-11-01
CA2742248C (en) 2014-01-14
US20110245500A1 (en) 2011-10-06
ZA201103154B (en) 2012-01-25
US8183243B2 (en) 2012-05-22
CL2011001073A1 (es) 2011-10-07
BRPI0921063A2 (pt) 2015-08-25
EP2350060B1 (en) 2013-09-18
ECSP11011026A (es) 2011-06-30
US20110224219A1 (en) 2011-09-15
CN102282141B (zh) 2014-09-10
JP2012508730A (ja) 2012-04-12
CO6362006A2 (es) 2012-01-20
AR074109A1 (es) 2010-12-22
MX2011004583A (es) 2011-06-01
EP2350060A4 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
TN2011000222A1 (en) Melanocortin receptor agonists
WO2007098474A8 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
IN2012DN01241A (ru)
WO2009098230A3 (en) Pesticidal mixtures
MX2013001493A (es) Composiciones orales que comprenden un compuesto de cinc y un agente anti-microbiano.
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MY154909A (en) Novel thiophene derivatives
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
IL192948A0 (en) Novel pyridine derivatives
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
MX2010007807A (es) Mezclas de plaguicidas.
TW200942524A (en) Novel aminomethyl benzene derivatives
MY178894A (en) Therapeutic compositions containing macitentan
MX2010008177A (es) Mezclas de plaguicidas.
TW200942530A (en) Pyridine compounds
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
MX2011008756A (es) Composicion insecticida que comprende un derivado de hidracida antranilica y un neonicotinoide.
WO2012030957A3 (en) Non-hygroscopic salts of 5-ht2c agonists
EP2238105A4 (en) NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH
WO2009098228A3 (en) Pesticidal mixtures
TW200639164A (en) Novel salt form of a dopamine agonist
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
MX2009012761A (es) Neramexano para el tratamiento de nistagmo.
EP2307394A4 (en) NOVEL COMPOUNDS, CORRESPONDING ISOMER OR CORRESPONDING PHARMACEUTICALLY ACCEPTABLE SALTS AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM